Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.